![]() |
||
![]() ![]() |
||
Find a Study5611: Potential Modulatory Role of Osteoprotegerin in Bone Metabolism of Patients with 21-Hydroxylase DeficiencyStatus: Recruiting Study Summary Please Note: The Rare Diseases Clinical Research Network will make every effort to enroll all the patients we can, but we cannot make any guarantees that we will be able to enroll everyone in a particular study who wants to participate. Background Congenital adrenal hyperplasia (CAH) is a genetic defect of the glands that produce hormones. The most common form of CAH is steroid 21-hydroxylase deficiency (21OHD). This study will look at bone health in CAH. Doctors want to learn how CAH and its treatment affect bones. About this Study Doctors will compare people who have CAH to people who do not have CAH. If you take part in this study, you will only need to come in for one office visit. About 40 people (20 with 21OHD and 20 without 21OHD) will be enrolled over a 2 year period. If you decide to take part, your medical records will be looked at and you will be evaluated by the following:
Targeted Enrollment To be eligible to participate, you must:
You are not eligible to participate if:
How to Participate: In order to participate in a study, you must personally contact the study coordinator of any of the participating institutions by phone or by e-mail. Please use the information below to inquire about participation.
Join the Contact Registry for: Congenital Adrenal Hyperplasia |
||
Home | Glossary | Frequently Asked Questions | Contact Web Master | Accessibility | Disclaimer | Site Map |
||